| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076770P | 2014-11-07 | 2014-11-07 | |
| US201462088061P | 2014-12-05 | 2014-12-05 | |
| PCT/US2015/059571WO2016073915A1 (en) | 2014-11-07 | 2015-11-06 | Stable protein solution formulation containing high concentration of an anti-vegf antibody |
| Publication Number | Publication Date |
|---|---|
| BR112017008660A2true BR112017008660A2 (pt) | 2017-12-26 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017008660ABR112017008660A2 (pt) | 2014-11-07 | 2015-11-06 | formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf |
| BR112017008093-1ABR112017008093A2 (pt) | 2014-11-07 | 2015-11-06 | processos para tratamento de doenças oculares |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017008093-1ABR112017008093A2 (pt) | 2014-11-07 | 2015-11-06 | processos para tratamento de doenças oculares |
| Country | Link |
|---|---|
| US (5) | US10689438B2 (pt) |
| EP (2) | EP3215123A1 (pt) |
| JP (6) | JP6753848B2 (pt) |
| KR (4) | KR20170082526A (pt) |
| CN (3) | CN107635580A (pt) |
| AU (6) | AU2015342818B2 (pt) |
| BR (2) | BR112017008660A2 (pt) |
| CA (2) | CA2966646A1 (pt) |
| CL (2) | CL2017001115A1 (pt) |
| CO (1) | CO2017004596A2 (pt) |
| EA (1) | EA201790989A1 (pt) |
| EC (1) | ECSP17034829A (pt) |
| GT (1) | GT201700096A (pt) |
| IL (5) | IL251642B (pt) |
| MX (3) | MX383399B (pt) |
| MY (2) | MY193913A (pt) |
| NZ (1) | NZ730821A (pt) |
| PE (1) | PE20170780A1 (pt) |
| PH (3) | PH12021550147A1 (pt) |
| RU (1) | RU2722643C2 (pt) |
| SG (3) | SG10201913565RA (pt) |
| TN (1) | TN2017000128A1 (pt) |
| TW (4) | TWI705827B (pt) |
| WO (2) | WO2016073915A1 (pt) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2643469T3 (es) | 2006-04-07 | 2017-11-23 | Aerpio Therapeutics, Inc. | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| DK3444274T3 (da) | 2008-06-25 | 2021-03-22 | Novartis Ag | Stabile og opløselige antistoffer, der hæmmer TNF |
| SI2752428T1 (sl) | 2008-06-25 | 2020-03-31 | Novartis Ag | Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa |
| BRPI1006897A2 (pt) | 2009-07-06 | 2015-09-08 | Akebia Therapeutics Inc | compostos, composições e métodos de prevenção da metástase de células cancerosas. |
| KR20180023015A (ko) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| HK1201178A1 (en) | 2011-10-13 | 2015-08-28 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10894083B2 (en) | 2015-01-28 | 2021-01-19 | Pfizer Inc. | Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3352856B1 (en) | 2015-09-23 | 2021-08-18 | Aerpio Pharmaceuticals, Inc. | Activators of tie-2 for use in treating intraocular pressure |
| HK1257295A1 (zh) | 2015-12-04 | 2019-10-18 | Novartis Ag | 用於免疫腫瘤學的組合物和方法 |
| CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
| CA3030298A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.) |
| US11254738B2 (en)* | 2016-09-07 | 2022-02-22 | The Governing Council Of The University Of Toronto Banting Institute | Synthetic antibodies against VEGF and their uses |
| EP3518971A4 (en)* | 2016-09-28 | 2020-05-13 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| JOP20190103B1 (ar) | 2016-11-18 | 2023-09-17 | Astellas Pharma Inc | شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري |
| EP3601561A2 (en) | 2017-03-22 | 2020-02-05 | Novartis AG | Compositions and methods for immunooncology |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| CN109562166B (zh)* | 2017-04-28 | 2021-04-02 | 苏州思坦维生物技术股份有限公司 | 一种眼用药物组合物及其用途 |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| WO2019020777A1 (en)* | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| CN111315213B (zh) | 2017-10-06 | 2023-09-12 | 普罗塞纳生物科学有限公司 | 抗甲状腺素运载蛋白抗体 |
| KR102581734B1 (ko) | 2017-10-06 | 2023-09-22 | 네오토프 뉴로사이언스 리미티드 | 트랜스타이레틴의 검출 방법 |
| CU20200042A7 (es) | 2017-11-29 | 2021-03-11 | Prothena Biosciences Ltd | Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina |
| EP4279135A3 (en) | 2017-11-30 | 2024-02-21 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat diabetic retinopathy |
| CA3088355A1 (en)* | 2018-02-06 | 2019-08-15 | F. Hoffmann-La Roche Ag | Treatment of ophthalmologic diseases |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| AU2019235577B2 (en)* | 2018-03-16 | 2021-09-30 | Novartis Ag | Methods for treating ocular diseases |
| EP3768706A1 (en)* | 2018-03-23 | 2021-01-27 | AbbVie Deutschland GmbH & Co. KG | Stable aqueous anti-tau antibody formulations |
| WO2019200006A2 (en)* | 2018-04-10 | 2019-10-17 | Askgene Pharma Inc. | Novel angiopoietin 2, vegf dual antagonists |
| MA52570A (fr) | 2018-05-10 | 2021-03-17 | Regeneron Pharma | Formulations contenant des protéines de fusion du récepteur vegf à haute concentration |
| US12202908B2 (en) | 2018-05-17 | 2025-01-21 | Astellas Pharma Inc. | Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand |
| CN113164597B (zh) | 2018-09-24 | 2025-02-28 | 视点制药公司 | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 |
| TW202027794A (zh) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | 血管生成素樣３多肽之持續遞送 |
| TWI835880B (zh)* | 2018-10-10 | 2024-03-21 | 日商安斯泰來製藥股份有限公司 | 含有標識部－抗人類抗體Ｆａｂ片段複合體之醫藥組成物 |
| BR112021007946A2 (pt)* | 2018-10-29 | 2021-08-03 | F. Hoffmann-La Roche Ag | formulação de anticorpo |
| MX2021005382A (es) | 2018-11-07 | 2021-11-12 | Applied Molecular Transport Inc | Vehiculos derivados de cholix para suministro oral de carga util heterologa. |
| BR112021011290A2 (pt)* | 2018-12-18 | 2021-11-03 | Novartis Ag | Formulação de solução de proteína contendo alta concentração de um anticorpo anti-vegf |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| TWI862583B (zh) | 2019-04-26 | 2024-11-21 | 美商愛德維仁生物科技公司 | 用於玻璃體內遞送之變異體aav蛋白殼 |
| US11253502B2 (en) | 2019-04-29 | 2022-02-22 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the Schlemm's canal |
| PH12022550330A1 (en) | 2019-08-16 | 2023-02-06 | Applied Molecular Transport Inc | Compositions, formulations, and interleukin production and purification |
| CN114786731A (zh)* | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| CN111217834B (zh)* | 2020-02-21 | 2021-10-26 | 维眸生物科技（上海）有限公司 | Rock激酶抑制剂的硝基氧衍生物 |
| CN113698478A (zh)* | 2020-05-21 | 2021-11-26 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其稳定制剂 |
| KR20220001106A (ko) | 2020-06-29 | 2022-01-05 | (주)메디톡스 | 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체 |
| UY39324A (es) | 2020-07-16 | 2022-02-25 | Novartis Ag | Anticuerpos anti-betacelulina, sus fragmentos, moléculas de unión multiespecíficas, casetes de expresión, composiciones y métodos de tratamiento. |
| IL308505A (en)* | 2021-05-17 | 2024-01-01 | Regeneron Pharma | Continuous high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders |
| CN113940997B (zh)* | 2021-12-21 | 2022-04-08 | 迈威(上海)生物科技股份有限公司 | 一种双特异性抗体的稳定制剂 |
| CN119584953A (zh)* | 2022-09-16 | 2025-03-07 | 齐鲁制药有限公司 | 一种稳定的高浓度自缓冲药物组合物 |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en)* | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JO3000B1 (ar)* | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP2311433A3 (en) | 2004-10-21 | 2011-08-10 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
| WO2007011873A2 (en)* | 2005-07-15 | 2007-01-25 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PT2944306T (pt)* | 2006-06-16 | 2021-02-15 | Regeneron Pharma | Formulações antagonistas de vegf adequadas para administração intravitreal |
| US20090175847A1 (en) | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
| AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| DK3444274T3 (da) | 2008-06-25 | 2021-03-22 | Novartis Ag | Stabile og opløselige antistoffer, der hæmmer TNF |
| SI2752428T1 (sl) | 2008-06-25 | 2020-03-31 | Novartis Ag | Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa |
| KR102157097B1 (ko) | 2008-06-25 | 2020-09-18 | 노바르티스 아게 | Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체 |
| MX344076B (es) | 2008-06-30 | 2016-12-05 | Esbatech Alcon Biomed Res Unit | Polipeptidos funcionalizados. |
| MX2012006831A (es) | 2009-12-21 | 2012-08-17 | Genentech Inc | Formacion de anticuerpos. |
| US9458240B2 (en) | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| KR20180023015A (ko)* | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| AR086823A1 (es)* | 2011-06-30 | 2014-01-22 | Genentech Inc | Formulaciones de anticuerpo anti-c-met, metodos |
| BR112014009030A2 (pt)* | 2011-10-20 | 2017-09-12 | Esbatech A Novartis Co Llc | anticorpo de ligação a antígenos múltiplos estável |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| UA117466C2 (uk)* | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| RU2694055C2 (ru) | 2013-03-13 | 2019-07-09 | Дженентек, Инк. | Составы антител |
| WO2015086830A1 (en)* | 2013-12-13 | 2015-06-18 | Delenex Therapeutics Ag | Skin penetrating polypeptides |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| MX2016016836A (es)* | 2014-06-17 | 2017-07-27 | Clearside Biomedical Inc | Metodos y dispositivos para tratar trastornos oculares posteriores. |
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| AU2019235577B2 (en) | 2018-03-16 | 2021-09-30 | Novartis Ag | Methods for treating ocular diseases |
| BR112021011290A2 (pt) | 2018-12-18 | 2021-11-03 | Novartis Ag | Formulação de solução de proteína contendo alta concentração de um anticorpo anti-vegf |
| Publication | Publication Date | Title |
|---|---|---|
| BR112017008660A2 (pt) | formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| BR112014027116A2 (pt) | formulação de anticorpo | |
| EP4233892A3 (en) | Stable anti-ifnar1 formulation | |
| BR112018008805A2 (pt) | proteínas de função dupla e composição farmacêutica que compreende a mesma | |
| BR112021011290A2 (pt) | Formulação de solução de proteína contendo alta concentração de um anticorpo anti-vegf | |
| WO2012076670A3 (en) | Antibody formulation | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| MX2019014666A (es) | Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo. | |
| AR130115A2 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf |
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | Free format text:DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. | |
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |